Literature DB >> 16862578

The proteasomal inhibition model of Parkinson's disease: "Boon or bust"?

Flint Beal, Anthony Lang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16862578     DOI： 10.1002/ana.20939

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  9 in total

1.  Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems.

Authors:  Nicholas MacInnes; Mahmoud M Iravani; Elaine Perry; Margaret Piggott; Robert Perry; Peter Jenner; Clive Ballard
Journal:  J Neural Transm (Vienna)       Date:  2008-04-10       Impact factor: 3.575

Review 2.  Neuroprotection in Parkinson's disease: myth or reality?

Authors:  Tiffini Voss; Bernard Ravina
Journal:  Curr Neurol Neurosci Rep       Date:  2008-07       Impact factor: 5.081

Review 3.  Exploring the link between glucocerebrosidase mutations and parkinsonism.

Authors:  Wendy Westbroek; Ann Marie Gustafson; Ellen Sidransky
Journal:  Trends Mol Med       Date:  2011-07-01       Impact factor: 11.951

4.  A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

Authors:  Karl Kieburtz; Michael P McDermott; Tiffini S Voss; Jody Corey-Bloom; Lisa M Deuel; E Ray Dorsey; Stewart Factor; Michael D Geschwind; Karen Hodgeman; Elise Kayson; Sarah Noonberg; Michael Pourfar; Karen Rabinowitz; Bernard Ravina; Juan Sanchez-Ramos; Lynn Seely; Francis Walker; Andrew Feigin
Journal:  Arch Neurol       Date:  2010-02

Review 5.  Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.

Authors:  Britney N Lizama; Amy M Palubinsky; BethAnn McLaughlin
Journal:  Neurochem Int       Date:  2017-08-26       Impact factor: 3.921

6.  Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration.

Authors:  Brian N Mathur; M Diana Neely; Melanie Dyllick-Brenzinger; Anurag Tandon; Ariel Y Deutch
Journal:  Brain Res       Date:  2007-07-20       Impact factor: 3.252

7.  Adaptation to chronic MG132 reduces oxidative toxicity by a CuZnSOD-dependent mechanism.

Authors:  Rehana K Leak; Michael J Zigmond; Anthony K F Liou
Journal:  J Neurochem       Date:  2008-05-03       Impact factor: 5.372

Review 8.  The Proteasome Inhibition Model of Parkinson's Disease.

Authors:  Eduard Bentea; Lise Verbruggen; Ann Massie
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

Review 9.  Role of the ubiquitin proteasome system in Parkinson's disease.

Authors:  Kah-Leong Lim; Jeanne M M Tan
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.